TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis
Brief Summary: This study will test the efficacy and safety of topical diclofenac sodium gel in the treatment of hand osteoarthritis.


Options:
A: Arm Label: MEDIC; Type: ACTIVE_COMPARATOR; Interventions: Other: Neuromuscular training (NEMEX-TJR), Drug: Paracetamol, Drug: Burana, Drug: Pantoprazole, Behavioral: Dietary counseling, Behavioral: Patient education, Other: Insoles | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information | Intervention Type: OTHER; Name: Neuromuscular training (NEMEX-TJR); Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Information; Assigned to Arm(s): Standard treatment | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): MEDIC | Intervention Type: DRUG; Name: Burana; Assigned to Arm(s): MEDIC | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Dietary counseling; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Patient education; Assigned to Arm(s): MEDIC | Intervention Type: OTHER; Name: Insoles; Assigned to Arm(s): MEDIC
B: Arm Label: COV155; Type: EXPERIMENTAL; Interventions: Drug: COV155 | Intervention Type: DRUG; Name: COV155; Assigned to Arm(s): COV155
C: Intervention Type: DRUG; Name: Glucosamine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Diclofenac sodium gel 1%; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis
Brief Summary: This study will test the efficacy and safety of topical diclofenac sodium gel in the treatment of hand osteoarthritis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ketoprofen in Diractin® | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ketoprofen in Diractin®; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Diclofenac topical sodium gel 1%; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Diclofenac Sodium Gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Diclofenac Sodium Gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis
Brief Summary: This study will test the efficacy and safety of topical diclofenac sodium gel in the treatment of hand osteoarthritis.


Options:
A: Arm Label: LAYLA; Type: EXPERIMENTAL; Interventions: Drug: LAYLA tablet | Arm Label: JOINS; Type: ACTIVE_COMPARATOR; Interventions: Drug: JOINS tablet | Intervention Type: DRUG; Name: LAYLA tablet; Assigned to Arm(s): LAYLA | Intervention Type: DRUG; Name: JOINS tablet; Assigned to Arm(s): JOINS
B: Arm Label: COV155; Type: EXPERIMENTAL; Interventions: Drug: COV155 | Intervention Type: DRUG; Name: COV155; Assigned to Arm(s): COV155
C: Intervention Type: DRUG; Name: Diclofenac topical sodium gel 1%; Assigned to Arm(s): N/A
D: Arm Label: Tramadol Hydrochloride/Acetaminophen ER; Type: EXPERIMENTAL; Interventions: Drug: Tramadol HCl/Acetaminophen ER | Arm Label: Tramadol HCl/Acetaminophen IR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tramadol HCl/Acetaminophen IR | Intervention Type: DRUG; Name: Tramadol HCl/Acetaminophen ER; Assigned to Arm(s): Tramadol Hydrochloride/Acetaminophen ER | Intervention Type: DRUG; Name: Tramadol HCl/Acetaminophen IR; Assigned to Arm(s): Tramadol HCl/Acetaminophen IR

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis
Brief Summary: This study will test the efficacy and safety of topical diclofenac sodium gel in the treatment of hand osteoarthritis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Diclofenac Sodium Gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Diclofenac Sodium Gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Diclofenac topical sodium gel 1%; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
Brief Summary: This study will test the efficacy and safety of topical diclofenac sodium gel in the treatment of knee osteoarthritis.


Options:
A: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Diclofenac Sodium Gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Diclofenac Sodium Gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Diclofenac topical sodium gel 1%; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
Brief Summary: This study will test the efficacy and safety of topical diclofenac sodium gel in the treatment of knee osteoarthritis.


Options:
A: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Diclofenac topical sodium gel 1%; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Diclofenac Sodium Gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Diclofenac Sodium Gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
Brief Summary: This study will test the efficacy and safety of topical Voltaren in the treatment of knee osteoarthritis.


Options:
A: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ketoprofen in Diractin® | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: ketoprofen in Diractin® | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: celecoxib | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ketoprofen in Diractin®; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ketoprofen in Diractin®; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): 3
C: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
Brief Summary: This study will test the efficacy and safety of topical Voltaren in the treatment of knee osteoarthritis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Diclofenac Sodium Gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Diclofenac Sodium Gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Diclofenac Topical Sodium Gel 1%; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A One Year, Open-label, Single-arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/Day) in Patients Diagnosed With Transfusion-dependent Iron Overload
Brief Summary: This study uses a single arm, multi-center, open-label trial design. The study will assess the efficacy and safety of 52 weeks of treatment with deferasirox (ICL670) in patients with evidence of transfusion induced iron overload.


Options:
A: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670) | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP, DFO | Intervention Type: DRUG; Name: DFP (ferriprox) and deferasirox (ICL 670); Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: DFP, DFO; Assigned to Arm(s): arm 2
B: Arm Label: ICL670; Type: EXPERIMENTAL; Interventions: Drug: ICL670 | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: deferoxamine | Intervention Type: DRUG; Name: ICL670; Assigned to Arm(s): ICL670 | Intervention Type: DRUG; Name: deferoxamine; Assigned to Arm(s): Deferoxamine
C: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Core Study: Deferasirox, Drug: Deferasirox | Arm Label: Deferasirox Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Core Study: Deferoxamine, Drug: Deferoxamine | Arm Label: Extension: deferoxamine to deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferoxamine to deferasirox | Arm Label: Extension: deferasirox to deferoxamine; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Core Study: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Core Study: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo | Intervention Type: DRUG; Name: Extension: deferoxamine to deferasirox; Assigned to Arm(s): Extension: deferoxamine to deferasirox | Intervention Type: DRUG; Name: Extension: deferasirox to deferoxamine; Assigned to Arm(s): Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo
D: Arm Label: ICL670 (Deferasirox); Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): ICL670 (Deferasirox)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A One Year, Open-label, Single-arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/Day) in Patients Diagnosed With Transfusion-dependent Iron Overload
Brief Summary: This study uses a single arm, multi-center, open-label trial design. The study will assess the efficacy and safety of 52 weeks of treatment with deferasirox (ICL670) in patients with evidence of transfusion induced iron overload.


Options:
A: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Core Study: Deferasirox, Drug: Deferasirox | Arm Label: Deferasirox Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Core Study: Deferoxamine, Drug: Deferoxamine | Arm Label: Extension: deferoxamine to deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferoxamine to deferasirox | Arm Label: Extension: deferasirox to deferoxamine; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Core Study: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Core Study: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo | Intervention Type: DRUG; Name: Extension: deferoxamine to deferasirox; Assigned to Arm(s): Extension: deferoxamine to deferasirox | Intervention Type: DRUG; Name: Extension: deferasirox to deferoxamine; Assigned to Arm(s): Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone (DFP) | Intervention Type: DRUG; Name: Deferiprone (DFP) and Deferoxamine (DFO); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Deferiprone (DFP); Assigned to Arm(s): 2
C: Arm Label: ICL670 (Deferasirox); Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): ICL670 (Deferasirox)
D: Arm Label: Thalassemia cohort; Type: N/A; Interventions: N/A | Arm Label: Successful SCT cohort; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A One Year, Open-label, Single-arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/Day) in Patients Diagnosed With Transfusion-dependent Iron Overload
Brief Summary: This study uses a single arm, multi-center, open-label trial design. The study will assess the efficacy and safety of 52 weeks of treatment with deferasirox (ICL670) in patients with evidence of transfusion induced iron overload.


Options:
A: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox
B: Arm Label: ICL670 (Deferasirox); Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): ICL670 (Deferasirox)
C: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Core Study: Deferasirox, Drug: Deferasirox | Arm Label: Deferasirox Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Core Study: Deferoxamine, Drug: Deferoxamine | Arm Label: Extension: deferoxamine to deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferoxamine to deferasirox | Arm Label: Extension: deferasirox to deferoxamine; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Core Study: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Core Study: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo | Intervention Type: DRUG; Name: Extension: deferoxamine to deferasirox; Assigned to Arm(s): Extension: deferoxamine to deferasirox | Intervention Type: DRUG; Name: Extension: deferasirox to deferoxamine; Assigned to Arm(s): Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferoxamine | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferasirox | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Arm 1, Arm 3 | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Arm 2, Arm 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Brief Summary: Placebo-controlled prospective randomized phase III study to investigate the antiproliferative effect of octreotide in patients with metastasized neuroendocrine tumors of the midgut


Options:
A: Arm Label: BEZ235; Type: EXPERIMENTAL; Interventions: Drug: BEZ235 | Arm Label: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: BEZ235; Assigned to Arm(s): BEZ235 | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus
B: Arm Label: Octreotide LAR (Long Acting Release); Type: EXPERIMENTAL; Interventions: Drug: Octreotide LAR (Long-acting release) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Octreotide LAR (Long-acting release); Assigned to Arm(s): Octreotide LAR (Long Acting Release) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Everolimus 10 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus 10 mg/day | Intervention Type: DRUG; Name: Everolimus Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 177Lu-DOTA-EB-TATE 1; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 1 | Arm Label: 177Lu-DOTA-EB-TATE 2; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 2 | Arm Label: 177Lu-DOTA-EB-TATE 3; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 3 | Arm Label: 177Lu-DOTA-TATE; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-TATE | Arm Label: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine); Type: EXPERIMENTAL; Interventions: Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine) | Arm Label: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine); Type: EXPERIMENTAL; Interventions: Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine) | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 1; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 1 | Intervention Type: DRUG; Name: 177Lu-DOTA-TATE; Assigned to Arm(s): 177Lu-DOTA-TATE | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 2; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 2 | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 3; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 3 | Intervention Type: DRUG; Name: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine); Assigned to Arm(s): 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine) | Intervention Type: DRUG; Name: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine); Assigned to Arm(s): 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study)
Brief Summary: To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.


Options:
A: Arm Label: The Red Heart Pill 2b (Polypill) (A); Type: EXPERIMENTAL; Interventions: Drug: Red Heart Pill 2b (Polypill) | Arm Label: Standard Practice Group (B); Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Practice | Intervention Type: DRUG; Name: Red Heart Pill 2b (Polypill); Assigned to Arm(s): The Red Heart Pill 2b (Polypill) (A) | Intervention Type: OTHER; Name: Standard Practice; Assigned to Arm(s): Standard Practice Group (B)
B: Arm Label: FDC Fixed Dose Combination; Type: EXPERIMENTAL; Interventions: Drug: FDC | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Separately drugs, simvastatin, aspirin and ramipril | Intervention Type: DRUG; Name: FDC; Assigned to Arm(s): FDC Fixed Dose Combination | Intervention Type: DRUG; Name: Separately drugs, simvastatin, aspirin and ramipril; Assigned to Arm(s): Conventional treatment
C: Arm Label: Telmisartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Telmisartan | Arm Label: Telmisartan/hydrochlorothiazide; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/hydrochlorothiazide | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Telmisartan/hydrochlorothiazide
D: Intervention Type: DRUG; Name: Amlodipine/atorvastatin single pill; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Extension Study Evaluating The Long Term Efficacy , Safety And Tolerability Of Oral Ziprasidone In The Treatment Of Patients Who Have Successfully Completed The Previous Ziprasidone Study A1281031
Brief Summary: Open label extension study of Ziprasidone, evaluation of safety of long term use of ziprasidone


Options:
A: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Ziprasidone | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): A1
B: Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Quetiapine, Drug: Ziprasidone | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Risperidone, Drug: Ziprasidone | Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Arm Label: Ziprasidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Quetiapine | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone
C: Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: perphenazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ziprasidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: clozapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluphenazine decanoate; Assigned to Arm(s): N/A

Answer: A